Trial Profile
Pharmacokinetics and safety of letermovir, a novel anti-human-cytomegalovirus drug, in renally impaired patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Apr 2017
Price :
$35
*
At a glance
- Drugs Letermovir (Primary)
- Indications Cytomegalovirus infections
- Focus Adverse reactions; Pharmacokinetics
- 26 Mar 2017 Results published in the British Journal of Clinical Pharmacology
- 03 Sep 2015 New trial record